Innovent Biologics vs Sichuan Kelun-Biotech: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Innovent Biologics Inc (1801.HK)

Q3 202622 Jun – 20 Aug 2026

▲3▼1

Innovent advances pipeline, licensing, and revenue; risks persist

Pipeline and licensing progress Innovent started Phase 3 trials for a fast-tracked myeloma antibody, gained China rights to Verzenio and Vanflyta, licensed IBI355 to Spero for up to $1.1B, and filed the world's first weekly oral GLP-1.
These pipeline and licensing moves are key new developments that can drive future growth and investor optimism.
Strong revenue growth First-half product revenue rose over 55% to 8.2 billion yuan, showing strong commercial execution and underlying business momentum.
Revenue growth is a fundamental driver of stock performance and reflects the company's financial health.
Sector re-rating on licensing activity A sector re-rating driven by record Chinese licensing activity boosted valuations across the biotech space, lifting Innovent's shares.
This external factor improved sentiment and valuation multiples for the entire sector, including Innovent.
Risks from trial and deal flow Sector rallies can cool if deal flow slows, and pipeline bets like IBI3003 and IBI3042 depend on costly, uncertain late-stage trials and regulatory outcomes.
These risks could negatively impact the stock if they materialize, providing a balanced view.

August 202627 Jul – 20 Aug 2026

▲4

Innovent adds Daiichi deal and weekly GLP-1 filing as sector re-rates

World-first weekly oral GLP-1 enters clinic Innovent's IBI3042 became the first small-molecule weekly oral GLP-1 to reach clinical stage, with China's drug regulator accepting the filing. A once-weekly pill would be easier for patients than injections, so success could open a large obesity and diabetes market and lift long-term sales hopes.
New pipeline milestone that expands Innovent's biggest growth opportunity beyond current products.
Wins China rights to Daiichi Sankyo's Vanflyta Innovent secured exclusive China commercialization rights for Vanflyta, a leukemia drug approved in June 2026, while Daiichi Sankyo handles development and supply. This adds a near-term oncology product to sell through Innovent's existing hospital network, lifting revenue without big new research spending.
A concrete new commercial deal that adds revenue and shows Innovent's partnering strength.
First-half product revenue up over 55% Innovent's first-half product revenue topped 8.2 billion yuan, up more than 55% year on year, reported alongside strong results from BeiGene and RemeGen. Faster product sales show its medicines are being adopted widely, which supports profit growth and gives the stock a fundamental reason to rise.
Actual reported sales growth is the core evidence behind the share price move.
Sector re-rating on record licensing and Moderna data Chinese drug licensing deals hit about $99.7 billion in the first half, roughly double all of 2024, and Moderna's cancer vaccine success lifted biotech shares globally. Innovent landed billion-dollar overseas deals, so investors are paying more for its pipeline. Counterweight: sector rallies can cool if deal flow slows.
Explains the broad demand backdrop pushing innovative drug stocks, including Innovent, higher.

Latest27 Jul – 20 Aug 2026

▲4

Innovent adds Daiichi deal and weekly GLP-1 filing as sector re-rates

World-first weekly oral GLP-1 enters clinic Innovent's IBI3042 became the first small-molecule weekly oral GLP-1 to reach clinical stage, with China's drug regulator accepting the filing. A once-weekly pill would be easier for patients than injections, so success could open a large obesity and diabetes market and lift long-term sales hopes.
New pipeline milestone that expands Innovent's biggest growth opportunity beyond current products.
Wins China rights to Daiichi Sankyo's Vanflyta Innovent secured exclusive China commercialization rights for Vanflyta, a leukemia drug approved in June 2026, while Daiichi Sankyo handles development and supply. This adds a near-term oncology product to sell through Innovent's existing hospital network, lifting revenue without big new research spending.
A concrete new commercial deal that adds revenue and shows Innovent's partnering strength.
First-half product revenue up over 55% Innovent's first-half product revenue topped 8.2 billion yuan, up more than 55% year on year, reported alongside strong results from BeiGene and RemeGen. Faster product sales show its medicines are being adopted widely, which supports profit growth and gives the stock a fundamental reason to rise.
Actual reported sales growth is the core evidence behind the share price move.
Sector re-rating on record licensing and Moderna data Chinese drug licensing deals hit about $99.7 billion in the first half, roughly double all of 2024, and Moderna's cancer vaccine success lifted biotech shares globally. Innovent landed billion-dollar overseas deals, so investors are paying more for its pipeline. Counterweight: sector rallies can cool if deal flow slows.
Explains the broad demand backdrop pushing innovative drug stocks, including Innovent, higher.

July 202622 Jun – 15 Jul 2026

▲4

Innovent advances novel drugs and expands commercial reach

Tri-specific antibody enters Phase 3 Innovent dosed the first patient in a Phase 3 trial of IBI3003 for multiple myeloma. This novel therapy showed strong early results and has FDA Fast Track status. Success could add a major new treatment to Innovent's pipeline, boosting future revenue prospects.
This is a new clinical milestone that could lead to a new drug approval and revenue stream.
Ollin raises $330M for eye drug Innovent's partner Ollin Biosciences raised $330 million to fund global Phase 3 trials of an eye drug discovered by Innovent. The trials will include China and South Korea. This validates Innovent's research and could bring milestone payments and royalties.
This is new partnership progress that could generate future revenue for Innovent.
Gains China rights to Verzenio Eli Lilly handed over sole commercialization rights for breast cancer drug Verzenio in mainland China to Innovent. The drug had about $221 million in sales last year. This expands Innovent's oncology portfolio and adds immediate revenue.
This is a new commercial agreement that directly boosts Innovent's product sales.
Licenses anti-CD40L antibody to Spero Innovent licensed IBI355, an autoimmune disease antibody, to Spero Therapeutics outside Greater China in a deal worth up to $1.1 billion. Innovent gets an upfront payment and potential milestones and royalties, while keeping China rights.
This is a new out-licensing deal that provides cash and validates Innovent's pipeline.

22 Jun – 15 Jul 2026

▲4

Innovent advances novel drugs and expands commercial reach

Tri-specific antibody enters Phase 3 Innovent dosed the first patient in a Phase 3 trial of IBI3003 for multiple myeloma. This novel therapy showed strong early results and has FDA Fast Track status. Success could add a major new treatment to Innovent's pipeline, boosting future revenue prospects.
This is a new clinical milestone that could lead to a new drug approval and revenue stream.
Ollin raises $330M for eye drug Innovent's partner Ollin Biosciences raised $330 million to fund global Phase 3 trials of an eye drug discovered by Innovent. The trials will include China and South Korea. This validates Innovent's research and could bring milestone payments and royalties.
This is new partnership progress that could generate future revenue for Innovent.
Gains China rights to Verzenio Eli Lilly handed over sole commercialization rights for breast cancer drug Verzenio in mainland China to Innovent. The drug had about $221 million in sales last year. This expands Innovent's oncology portfolio and adds immediate revenue.
This is a new commercial agreement that directly boosts Innovent's product sales.
Licenses anti-CD40L antibody to Spero Innovent licensed IBI355, an autoimmune disease antibody, to Spero Therapeutics outside Greater China in a deal worth up to $1.1 billion. Innovent gets an upfront payment and potential milestones and royalties, while keeping China rights.
This is a new out-licensing deal that provides cash and validates Innovent's pipeline.

Sichuan Kelun-Biotech (6990.HK)

Q3 202614 Jul – 8 Sep 2026

▲4▼1

Kelun-Biotech's pipeline and sales advance, but bribery probe clouds the story

Lung-cancer combo succeeds in Phase III The sac-TMT plus pembrolizumab combo met its main goal in first-line PD-L1-negative non-squamous lung cancer — the first ADC-plus-immunotherapy Phase III win in this group. Success lifts hopes for a big new use of its flagship drug, supporting the stock.
A major clinical win for the core drug is a key force behind the shares.
New dual-payload ADC enters clinic China's drug regulator cleared SKB565, the company's first dual-payload ADC, for human testing in advanced solid tumors. It is early-stage, but shows the pipeline keeps producing new candidates, which supports long-term growth expectations.
Pipeline progress is a core driver of biotech valuation.
Bribery allegations create legal and reputational risk A whistleblower letter alleges commercial bribery tied to the company's flagship drug sac-TMT, naming hospitals in Beijing. Kelun-Biotech denies it and threatens legal action. If proven, fines or sales restrictions could hurt; even unproven, it dents trust.
This is the main counterweight and a real risk to the stock.
Interim sales jump 112%, cash raised First-half product sales rose 112% to RMB 657 million, helped by insurance coverage for three sac-TMT uses and a new breast-cancer approval. The company also raised HK$2.72 billion in a share placing and dropped its 'B' marker, easing funding worries.
Strong commercial execution and fresh capital directly support the shares.
Partner's asthma drug moves to Phase III Partner Windward Bio reported positive Phase 2 asthma results for SKB378/WIN378, showing lasting lung-function gains with twice-yearly dosing, and started Phase 3. Success could bring milestone payments and royalties, adding a new growth path beyond cancer.
Partner validation of another pipeline asset is a fresh positive catalyst.

August 202614 Jul – 8 Sep 2026

▲4▼1

Kelun-Biotech's pipeline and sales advance, but bribery probe clouds the story

Lung-cancer combo succeeds in Phase III The sac-TMT plus pembrolizumab combo met its main goal in first-line PD-L1-negative non-squamous lung cancer — the first ADC-plus-immunotherapy Phase III win in this group. Success lifts hopes for a big new use of its flagship drug, supporting the stock.
A major clinical win for the core drug is a key force behind the shares.
New dual-payload ADC enters clinic China's drug regulator cleared SKB565, the company's first dual-payload ADC, for human testing in advanced solid tumors. It is early-stage, but shows the pipeline keeps producing new candidates, which supports long-term growth expectations.
Pipeline progress is a core driver of biotech valuation.
Bribery allegations create legal and reputational risk A whistleblower letter alleges commercial bribery tied to the company's flagship drug sac-TMT, naming hospitals in Beijing. Kelun-Biotech denies it and threatens legal action. If proven, fines or sales restrictions could hurt; even unproven, it dents trust.
This is the main counterweight and a real risk to the stock.
Interim sales jump 112%, cash raised First-half product sales rose 112% to RMB 657 million, helped by insurance coverage for three sac-TMT uses and a new breast-cancer approval. The company also raised HK$2.72 billion in a share placing and dropped its 'B' marker, easing funding worries.
Strong commercial execution and fresh capital directly support the shares.
Partner's asthma drug moves to Phase III Partner Windward Bio reported positive Phase 2 asthma results for SKB378/WIN378, showing lasting lung-function gains with twice-yearly dosing, and started Phase 3. Success could bring milestone payments and royalties, adding a new growth path beyond cancer.
Partner validation of another pipeline asset is a fresh positive catalyst.

Latest14 Jul – 8 Sep 2026

▲4▼1

Kelun-Biotech's pipeline and sales advance, but bribery probe clouds the story

Lung-cancer combo succeeds in Phase III The sac-TMT plus pembrolizumab combo met its main goal in first-line PD-L1-negative non-squamous lung cancer — the first ADC-plus-immunotherapy Phase III win in this group. Success lifts hopes for a big new use of its flagship drug, supporting the stock.
A major clinical win for the core drug is a key force behind the shares.
New dual-payload ADC enters clinic China's drug regulator cleared SKB565, the company's first dual-payload ADC, for human testing in advanced solid tumors. It is early-stage, but shows the pipeline keeps producing new candidates, which supports long-term growth expectations.
Pipeline progress is a core driver of biotech valuation.
Bribery allegations create legal and reputational risk A whistleblower letter alleges commercial bribery tied to the company's flagship drug sac-TMT, naming hospitals in Beijing. Kelun-Biotech denies it and threatens legal action. If proven, fines or sales restrictions could hurt; even unproven, it dents trust.
This is the main counterweight and a real risk to the stock.
Interim sales jump 112%, cash raised First-half product sales rose 112% to RMB 657 million, helped by insurance coverage for three sac-TMT uses and a new breast-cancer approval. The company also raised HK$2.72 billion in a share placing and dropped its 'B' marker, easing funding worries.
Strong commercial execution and fresh capital directly support the shares.
Partner's asthma drug moves to Phase III Partner Windward Bio reported positive Phase 2 asthma results for SKB378/WIN378, showing lasting lung-function gains with twice-yearly dosing, and started Phase 3. Success could bring milestone payments and royalties, adding a new growth path beyond cancer.
Partner validation of another pipeline asset is a fresh positive catalyst.